IS2946B - Lyfjablanda sem felur í sér andrógen - Google Patents

Lyfjablanda sem felur í sér andrógen

Info

Publication number
IS2946B
IS2946B IS8870A IS8870A IS2946B IS 2946 B IS2946 B IS 2946B IS 8870 A IS8870 A IS 8870A IS 8870 A IS8870 A IS 8870A IS 2946 B IS2946 B IS 2946B
Authority
IS
Iceland
Prior art keywords
pharmaceutical preparation
preparation containing
containing androgen
androgen
pharmaceutical
Prior art date
Application number
IS8870A
Other languages
English (en)
Other versions
IS8870A (is
Inventor
Robert Gyurik
Original Assignee
Auxilium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29251138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2946(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Auxilium Pharmaceuticals Inc filed Critical Auxilium Pharmaceuticals Inc
Publication of IS8870A publication Critical patent/IS8870A/is
Publication of IS2946B publication Critical patent/IS2946B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
IS8870A 2002-04-19 2010-01-06 Lyfjablanda sem felur í sér andrógen IS2946B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37410302P 2002-04-19 2002-04-19

Publications (2)

Publication Number Publication Date
IS8870A IS8870A (is) 2010-01-06
IS2946B true IS2946B (is) 2016-05-15

Family

ID=29251138

Family Applications (2)

Application Number Title Priority Date Filing Date
IS7535A IS2667B (is) 2002-04-19 2004-11-17 Lyfjablanda sem inniheldur andrógen
IS8870A IS2946B (is) 2002-04-19 2010-01-06 Lyfjablanda sem felur í sér andrógen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS7535A IS2667B (is) 2002-04-19 2004-11-17 Lyfjablanda sem inniheldur andrógen

Country Status (29)

Country Link
US (21) US7320968B2 (is)
EP (2) EP1425019B1 (is)
JP (1) JP2005519985A (is)
KR (2) KR100952786B1 (is)
CN (2) CN102357098B (is)
AR (2) AR039644A1 (is)
AT (1) ATE371456T1 (is)
AU (1) AU2003228612B2 (is)
BR (1) BR0309390A (is)
CA (1) CA2470200C (is)
CY (1) CY1109005T1 (is)
DE (1) DE60315939T2 (is)
DK (1) DK1425019T3 (is)
EA (1) EA009839B1 (is)
EG (1) EG24882A (is)
ES (2) ES2292964T3 (is)
IL (1) IL164547A (is)
IS (2) IS2667B (is)
LT (1) LT5235B (is)
LV (1) LV13303B (is)
MX (1) MXPA04010311A (is)
MY (1) MY139721A (is)
NO (1) NO335864B1 (is)
NZ (1) NZ535970A (is)
PL (1) PL213976B1 (is)
SA (1) SA03240158B1 (is)
TW (1) TWI362932B (is)
WO (1) WO2003088974A1 (is)
ZA (1) ZA200408422B (is)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
DE602004028284D1 (de) 2003-12-08 2010-09-02 Cpex Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
EA013430B1 (ru) * 2004-09-09 2010-04-30 Лаборатуар Безен Энтернасьональ Тестостероновые гели, включающие пропиленгликоль в качестве усилителя проницаемости
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
PT2450041T (pt) * 2005-10-12 2018-11-16 Unimed Pharmaceuticals Llc Gel de testosterona melhorado e método para a sua utilização
KR20110010763A (ko) * 2008-05-09 2011-02-07 톨마 인코포레이티드 피부/점막 질환을 치료하기 위한 프로구아닐
CN102056593A (zh) * 2008-06-05 2011-05-11 Cpex药品公司 胰岛素鼻用制剂
WO2011049776A1 (en) * 2009-10-22 2011-04-28 Cpex Pharmaceuticals, Inc. Therapeutically effective preparations of insulin
EP2640398A4 (en) 2010-11-18 2014-05-14 White Mountain Pharma Inc METHOD FOR TREATING CHRONIC OR BZW. NON-RELIABLE PAIN AND / OR INCREASE OF PATIENT PAIN THRESHOLD AND PHARMACEUTICAL COMPOSITION FOR USE THEREOF
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
KR20140045400A (ko) * 2011-05-15 2014-04-16 트리멜 바이오파마 에스알엘 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
US10568905B2 (en) * 2012-02-14 2020-02-25 Metabolic Therapy Inc. Pharmaceutical composition and method for treating retinal neurodegeneration
EP4186545A1 (en) 2012-04-06 2023-05-31 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
AU2013318229B2 (en) 2012-09-20 2017-07-06 Gkn Armstrong Wheels, Inc. Lock ring spreader
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US8785426B1 (en) 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
US20170014417A1 (en) 2015-07-14 2017-01-19 Lipp Life Sciences Llc Pharmaceutical administration system for the transdermal application of vardenafil
WO2019089942A1 (en) * 2017-11-02 2019-05-09 Rick Coulon Formulations for use in the transdermal delivery of proteasome inhibitors
CN112666197B (zh) * 2020-11-29 2022-11-04 山东大学 一种用于tbm的岩渣石英含量测试系统及方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US3989815A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Novel N-bis-azacyclopentan-2-onyl alkanes
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3991203A (en) * 1975-06-19 1976-11-09 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
BE843140A (fr) * 1975-06-19 1976-10-18 Aazacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
US4415563A (en) * 1980-04-04 1983-11-15 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclononan-2-ones
US4444762A (en) * 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4423040A (en) * 1980-04-04 1983-12-27 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclohexan-2-ones
US4424210A (en) * 1980-04-04 1984-01-03 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloalkan-2-ones
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US5270346A (en) 1986-01-31 1993-12-14 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US4992422A (en) * 1986-01-31 1991-02-12 Whitby Research, Inc. Compositions comprising 1-substituted azacycloalkanes
US4801586A (en) 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US4879275A (en) 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
US6190691B1 (en) * 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
DE19619045C1 (de) * 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6019997A (en) * 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
GB2355195B (en) * 1997-01-30 2001-09-12 Novartis Ag Oil-free pharmaceutical compositions containing cyclosporin A
DE29704393U1 (de) * 1997-03-11 1997-07-17 Aesculap Ag, 78532 Tuttlingen Vorrichtung zur präoperativen Bestimmung der Positionsdaten von Endoprothesenteilen
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
AU747041B2 (en) 1997-11-10 2002-05-09 Strakan International Limited Penetration enhancing and irritation reducing systems
US6980952B1 (en) * 1998-08-15 2005-12-27 Texas Instruments Incorporated Source normalization training for HMM modeling of speech
EP1031564A1 (en) * 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
FR2801507B1 (fr) 1999-11-30 2003-06-27 Pf Medicament Dispositif transdermique auto-adhesif comprenant un reservoir et une matrice contenant le meme principe actif, son procede de preparation et ses utilisations
PL203262B1 (pl) * 1999-12-08 2009-09-30 Pharmacia Corp Substancja lecznicza celekoksyb, jej zastosowanie i sposób jej wytwarzania, kompozyt celekoksyb-inhibitor krystalizacji i sposób jego wytwarzania, kompozycja farmaceutyczna i sposób jej wytwarzania
US6495124B1 (en) 2000-02-14 2002-12-17 Macrochem Corporation Antifungal nail lacquer and method using same
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
CA2418135C (en) * 2000-08-03 2011-09-20 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040002482A1 (en) 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
MXPA03001859A (es) * 2000-08-30 2004-05-21 Unimed Pharmaceuticals Inc Metodo para incrementar en la mujer testosterona y concentraciones de esteroides relacionados.
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
EP1315502B1 (en) 2000-08-30 2010-03-17 Unimed Pharmaceuticals, LLC Method for treating erectile dysfunction and increasing libido in men
CA2431566A1 (en) * 2000-12-11 2002-07-18 Testocreme, Llc Topical testosterone formulations and associated methods
EP1347764B1 (de) 2000-12-22 2007-03-14 Dr. August Wolff GmbH & Co. KG Arzneimittel Gelzusammensetzung auf alkoholischer basis zur behandlung von hypogonadismus durch transskrotale applikation
WO2002089849A1 (en) * 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US6980852B2 (en) 2002-01-25 2005-12-27 Subqiview Inc. Film barrier dressing for intravascular tissue monitoring system
EP1511494B1 (en) 2002-03-15 2020-08-19 Unimed Pharmaceuticals, LLC Androgen pharmaceutical composition and method for treating depression
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US20040259784A1 (en) 2003-06-18 2004-12-23 White Hillary D. Compositions and methods for treatment of muscle pain and muscle wasting

Also Published As

Publication number Publication date
EA009839B1 (ru) 2008-04-28
US7320968B2 (en) 2008-01-22
EA200401410A1 (ru) 2005-04-28
SA03240158B1 (ar) 2007-02-17
ES2292964T3 (es) 2008-03-16
AU2003228612B2 (en) 2006-05-04
AU2003228612A1 (en) 2003-11-03
NO20045019L (no) 2005-01-14
HK1098386A1 (en) 2007-07-20
NO335864B1 (no) 2015-03-09
AR039644A1 (es) 2005-03-02
EG24882A (en) 2010-12-01
LT5235B (lt) 2005-06-27
WO2003088974A1 (en) 2003-10-30
US20050192260A1 (en) 2005-09-01
IL164547A0 (en) 2005-12-18
US20210308145A1 (en) 2021-10-07
EP1741433B1 (en) 2012-11-07
IS7535A (is) 2004-11-17
KR100952786B1 (ko) 2010-04-14
CY1109005T1 (el) 2014-07-02
CN102357098A (zh) 2012-02-22
EP1425019B1 (en) 2007-08-29
LT2004101A (en) 2005-04-25
PL213976B1 (pl) 2013-05-31
US7608605B2 (en) 2009-10-27
US7608608B2 (en) 2009-10-27
HK1167332A1 (en) 2012-11-30
TWI362932B (en) 2012-05-01
HK1082682A1 (en) 2006-06-16
DK1425019T3 (da) 2008-02-04
EP1741433A1 (en) 2007-01-10
CN1662243B (zh) 2011-10-26
US20080275012A1 (en) 2008-11-06
MXPA04010311A (es) 2005-02-03
US20130281416A1 (en) 2013-10-24
US20080275013A1 (en) 2008-11-06
NZ535970A (en) 2006-12-22
US20090118252A1 (en) 2009-05-07
US8063029B2 (en) 2011-11-22
US20130059828A1 (en) 2013-03-07
US20100081640A1 (en) 2010-04-01
KR20090079266A (ko) 2009-07-21
ZA200408422B (en) 2006-06-28
US7608609B2 (en) 2009-10-27
AR087484A2 (es) 2014-03-26
US7935690B2 (en) 2011-05-03
US20090192132A1 (en) 2009-07-30
US20140343025A1 (en) 2014-11-20
US7608607B2 (en) 2009-10-27
US20080103120A1 (en) 2008-05-01
MY139721A (en) 2009-10-30
CA2470200A1 (en) 2003-10-30
LV13303B (en) 2006-08-20
US20210308146A1 (en) 2021-10-07
IS8870A (is) 2010-01-06
US20080108590A1 (en) 2008-05-08
CN102357098B (zh) 2014-12-17
US20090118251A1 (en) 2009-05-07
US20160129016A1 (en) 2016-05-12
IS2667B (is) 2010-08-15
US7608610B2 (en) 2009-10-27
EP1425019A1 (en) 2004-06-09
EP1425019A4 (en) 2004-11-17
KR100977896B1 (ko) 2010-08-24
US20090124590A1 (en) 2009-05-14
IL164547A (en) 2011-01-31
TW200408397A (en) 2004-06-01
US20090124589A1 (en) 2009-05-14
US20090131387A1 (en) 2009-05-21
DE60315939T2 (de) 2008-05-21
US20150283153A1 (en) 2015-10-08
CA2470200C (en) 2005-07-26
US20090192131A1 (en) 2009-07-30
KR20050011753A (ko) 2005-01-29
PL372083A1 (en) 2005-07-11
US7608606B2 (en) 2009-10-27
JP2005519985A (ja) 2005-07-07
US20090118250A1 (en) 2009-05-07
CN1662243A (zh) 2005-08-31
DE60315939D1 (de) 2007-10-11
BR0309390A (pt) 2005-02-09
ES2399900T3 (es) 2013-04-04
ATE371456T1 (de) 2007-09-15
US8178518B2 (en) 2012-05-15

Similar Documents

Publication Publication Date Title
IS2946B (is) Lyfjablanda sem felur í sér andrógen
IS8353A (is) Lyfjablanda sem felur í sér lantanefnasambönd
IS8460A (is) Lyfjafræðileg samsetning sem inniheldur kvetíapín
GB0213739D0 (en) Pharmaceutical compositions
IS7177A (is) Valdekoxíb samsetningar sem leysast upp í munni
IS7420A (is) Iressa lyfjablanda sem felur í sér vatnsleysanlega sellulósaafleiðu
IS7077A (is) Kristölluð samsetning sem inniheldur essítalópram
IL197889A (en) Pyridylvinylazacyclopentane compound and pharmaceutical compositions comprising same
IS8351A (is) Lyfjaafurðir sem fela í sér bisfosfónöt
IS6986A (is) Lyfjasamsetning í vökvaformi
IS2681B (is) Efnablöndur með tafða losun sem fela í sér lamótrígín
IL173930A0 (en) Pharmaceutical compositions containing forms of r-baclofen
IL174445A0 (en) Substituted isoquinolinone derivatives and pharmaceutical compositions containing the same
NO20052952D0 (no) Farmasoytisk sammensetning som innbefatter mikropartikler
IS8480A (is) Öragnir sem fela í sér sómatóstatínhliðstæður
IS2616B (is) Lyfjablanda sem felur í sér levóþýroxínnatríum
HU0302441D0 (en) Pharmaceutical compositions having antibiothic effect
GB0229258D0 (en) Medicinal compositions
IS7219A (is) Lyfjablanda sem inniheldur (R) -bíkalútamíð
IS7488A (is) Dreyfasamsetning í föstu formi
IS7835A (is) D-vítamínhliðstæður, blöndur sem fela í sér slíkar hliðstæður og notkun þeirra
EP1480649A4 (en) STABLE PHARMACEUTICAL COMPOSITIONS
GB0204392D0 (en) Pharmaceutical compound
IS6857A (is) Lyfjafræðileg samsetning sem innheldur sítalópram
IS7384A (is) Stöðug lyfjablanda sem felur í sér torsemíð afbrigði II